Aldeyra Therapeutics (ALDX) EBITDA (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported EBITDA for 14 consecutive years, with -$5.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 42.47% year-over-year to -$5.9 million; the trailing twelve-month figure through Jun 2026 stood at -$24.1 million (up 54.86% YoY), and the FY2025 full-year result was -$35.3 million, up 41.34% from the prior year.
• EBITDA retreated to -$5.9 million in Q2 2026 per ALDX's latest filing, from -$3.5 million in the prior quarter.
• Across five years, EBITDA topped out at -$3.5 million in Q1 2026 and bottomed at -$18.0 million in Q2 2024.
• Historically, EBITDA has averaged -$11.7 million across 5 years, with a median of -$10.4 million in 2023.
• The sharpest annual moves came in 2024 and 2026: EBITDA slumped 171.87% in 2024, then soared 65.98% in 2026.
• Over 5 years, EBITDA stood at -$13.7 million in 2022, then soared by 55.48% to -$6.1 million in 2023, then tumbled by 171.87% to -$16.6 million in 2024, then jumped by 59.78% to -$6.7 million in 2025, then gained by 12.26% to -$5.9 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$5.9 million, -$3.5 million, and -$6.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.